Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RS-C1001
- Development stage
- Phase 1
- Lead developer
- Qingdao Ruisen Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RS-C1001 is an investigational small molecule drug developed by Qingdao Ruisen Biotechnology. It is being studied as an oral therapy for the management of cholesterol levels, specifically targeting dyslipidemia. The drug is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effects are being evaluated in healthy Chinese subjects. Exploratory objectives include assessing the relationship between blood concentration and QTc interval and exploring effects on the biomarker FGF21. The precise mechanism of action has not been disclosed publicly[1][2][4].
Beyond the preview
Go deeper on RS-C1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RS-C1001.